First Trust Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

First Trust Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Sell	43,108 -223,997	-84%	-$7.38M	﹤0.01%	2113
2026 Q1	$8.55M	Sell	267,105 -12,596	-5%	-$410K	0.01%	1167
2025 Q4	$9.81M	Buy	+279,701	New	+$10.2M	0.01%	1110
2025 Q3	–	Sell	-131,430	Closed	-$2.38M	–	2687
2025 Q2	$2.38M	Buy	131,430 +12,378	+10%	+$226K	﹤0.01%	1743
2025 Q1	$2.44M	Buy	+119,052	New	+$2.65M	﹤0.01%	1695

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

First Trust Advisors's NAMS Position: Q2 2026 in Review

First Trust Advisors reduced its NewAmsterdam Pharma (NAMS) stake by 84% in Q2 2026, selling an estimated $7.38M and leaving 43,108 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

First Trust Advisors first reported a position in NAMS in Q1 2025 and has held it in 5 quarters since. The position peaked at $9.81M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

First Trust Advisors held 43,108 shares of NewAmsterdam Pharma worth $1.46M as of Q2 2026.
First Trust Advisors sold 223,997 NewAmsterdam Pharma shares in Q2 2026, an estimated $7.38M.
NewAmsterdam Pharma made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2113 holding.
First Trust Advisors first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 5 quarters since.
First Trust Advisors's NewAmsterdam Pharma position peaked at $9.81M in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.